Table 3.
Efficacy of (PEG-)IFN-free antiviral therapy in patients with HCV liver graft infection in controlled, prospective trials
| Author | Therapy regime | Treatment duration, weeks | Genotypea | n | SVR12, n |
|---|---|---|---|---|---|
| Charlton M, et al. [39] | LDV/RBV + RBV | 12–24 | 1, 4 | 229b | 214/229 (93%) |
| Charlton M, et al. [68] | SOF + RBV | 24 | 1, 3, 4 | 40 | 28/40 (70%) |
| Kwo PY, et al. [67] | DSV + OMV/PTV/r + RBV | 24 | 1 | 34 | 33/34 (97%) |
| Manns M, et al. [43]c | LDV/SOF +RBV | 12 or 24 | 1, 4 | 168c | 146/151 (97%)c |
| Poordad F, et al. [42]c | DCV/SOF + RBV | 12 | 1, 2, 3, 4, 6 | 53b | 50/53 (94%) |
| Pungpapong S, et al. [69]c | SMV + SOF ± RBV | 12 | 1 | 123c | 94/105 (90%)c |
a
Most studies investigated mainly genotype 1.
b
The complete study included patients prior to and after liver transplantation. 9 of 229 patients summarized here had graft cirrhosis and a MELD score > 15.
c
Preliminary results with regard to publication status or completed SVR12 (SVR not available in all patients enrolled into the study).
DCV = Daclatasvir; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir.